Thermo Fisher Scientific Ventures

Thermo Fisher Scientific Ventures is the corporate venture capital arm of Thermo Fisher Scientific, the Waltham-based life sciences giant. The fund directs capital into cutting-edge life sciences tools and analytical instruments, aligning with the parent’s vast portfolio across analytical instruments, specialty diagnostics, life sciences solutions, and laboratory products. Founders building novel reagents, instrumentation, single-cell tools, proteomics platforms, mass spec applications, or clinical diagnostics that complement Thermo Fisher’s commercial channels are a thesis fit. The corporate scale gives this venture arm unusually deep technical diligence capacity and broad reach into academic, pharma, and clinical labs.

The fund invests at Series A and Series B with check sizes of $5M to $25M, larger than most peers in this batch. It is United States based and concentrates on life sciences tools and diagnostics. AI focus is not stated, though many life sciences tools categories increasingly depend on computational platforms.

Founders should be prepared for technical diligence at depth, including evaluation by Thermo Fisher business unit leaders. A clear view on how the technology fits, extends, or could be distributed through the parent’s commercial platform will strengthen the conversation. Limited public information is available about partner contacts and specific portfolio composition, so introductions through Thermo Fisher business development or scientific advisory contacts are typically the most effective approach.